Iran Press/Iran News: Mohammad-Reza Salehi said on Tuesday: "Shafa Pharmed Company and Barekat Group are considering the request of these countries so that if possible, some surrounding countries could enter the third phase of the clinical trial of this vaccine."
The head of clinical studies of the Iranian coronavirus vaccine added: "If a contract is concluded and this vaccine is successfully passed, the third stage of human testing, these countries can also use this vaccine in their general vaccination program."
Regarding the safety of the Iranian coronavirus vaccine, Salehi said: "The safety and low side effects of the vaccine in the first stage were largely determined; So far, about 100 volunteers have received the vaccine having no serious side effects other than mild ones."
He added: "Although the determination of immunogenicity is more clear in the second and third stages, with the information obtained so far from the first stage, it made us very optimistic to achieve significant results in the second stage."
The implementation of the second phase of the human trials of the COVIran Barekat vaccine started two weeks ago and the third phase of this study will be implemented along with this phase.
214/216
Read More:
4 other volunteers receive Razi Covo-Pars vaccine
Razi Vaccine Head: 'Cov Pars', an excellent option for corona vaccination
